本文關(guān)鍵詞： 肺鱗狀細(xì)胞癌 程序性死亡配體 臨床病理特征 預(yù)后　出處：《山東醫(yī)藥》2017年08期 　論文類型：期刊論文

【摘要】：目的探討程序性死亡配體1(PD-L1)在肺鱗狀細(xì)胞癌(簡(jiǎn)稱肺鱗癌)發(fā)生、發(fā)展中的作用。方法選擇肺鱗癌組織90例份、正常肺組織15例份,采用免疫組化法檢測(cè)PD-L1表達(dá),分析PD-L1表達(dá)與患者臨床病理參數(shù)及預(yù)后的關(guān)系,應(yīng)用Cox比例風(fēng)險(xiǎn)回歸模型分析影響患者預(yù)后的危險(xiǎn)因素。結(jié)果肺鱗癌組織PD-L1陽(yáng)性表達(dá)率為66.67%(60/90),正常肺組織均為陰性表達(dá),二者比較P0.01。肺鱗癌組織PD-L1陽(yáng)性表達(dá)與患者性別、年齡、腫瘤直徑、吸煙史無(wú)關(guān)(P均0.05),與p TNM分期、淋巴結(jié)轉(zhuǎn)移有關(guān)(P均0.05)。PD-L1陽(yáng)性表達(dá)者中位生存時(shí)間明顯低于陰性表達(dá)者(P0.05)。Cox比例風(fēng)險(xiǎn)回歸模型分析顯示,PD-L1陽(yáng)性、淋巴結(jié)轉(zhuǎn)移、p TNM分期(Ⅲ期)是影響肺鱗癌預(yù)后的獨(dú)立危險(xiǎn)因素(P均0.05)。結(jié)論肺鱗癌組織PD-L1表達(dá)升高,其表達(dá)變化可促進(jìn)肺鱗癌的進(jìn)展和轉(zhuǎn)移;檢測(cè)PD-L1表達(dá)情況有助于判斷患者預(yù)后。
[Abstract]:Objective to investigate the role of programmed death ligand (PD-L1) in the development and progression of squamous cell carcinoma of the lung. Methods 90 cases of lung squamous cell carcinoma and 15 cases of normal lung tissue were selected. The expression of PD-L1 was detected by immunohistochemistry, and the relationship between the expression of PD-L1 and clinicopathological parameters and prognosis was analyzed. Cox proportional risk regression model was used to analyze the risk factors influencing the prognosis of patients. Results the positive rate of PD-L1 expression in lung squamous cell carcinoma was 66.67 / 60 / 90). The positive expression of PD-L1 in lung squamous cell carcinoma was not correlated with sex, age, tumor diameter and smoking history (P 0.05). Stage with p TNM. The median survival time of patients with positive expression of P0. 05 and PD-L1 in lymph node metastasis was significantly lower than that in patients with negative expression. PD-L1 positive and lymph node metastasis (stage 鈪，

本文編號(hào)：1467242